TuHURA Biosciences Announces Initial Data from Open-Label Study of IFx-2.0 in Metastatic Merkel Cell Carcinoma

Article summary

TuHURA Biosciences reported positive initial data from the first three patients in its open-label study of IFx-2.0 as an adjunctive therapy to Keytruda for metastatic Merkel Cell Carcinoma.